Neuroleptic treatment, symptoms of schizophrenia, and plasma homovanillic acid concentrations revisited.

J. Volavka,R. Douyon,A. Convit,P. Czobor,T. Cooper
DOI: https://doi.org/10.1001/ARCHPSYC.1992.01820120087017
1992-12-01
Archives of General Psychiatry
Abstract:To the Editor.— Davidson et al 1 reported that plasma homovanillic acid (pHVA) concentrations decreased in a group of neuroleptic responders (n=7) but were unchanged in nonresponders (n=13). Within the framework of a large experiment, 2 we collected analogous data. To replicate their results, we emulated their analyses with our data set. Our experiment 2 used 176 acutely exacerbated schizophrenic or schizoaffective patients. After a placebo period, they were randomly assigned to one of three plasma levels of haloperidol for 6 weeks. Weekly measures included haloperidol plasma levels, the Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI), and, in a subset of patients, pHVA (assayed with a modification of a published method 3 using gas chromatography/mass spectroscopy and deuterated HVA as an internal standard). Emulating the sampling criteria of Davidson et al, 1 we selected 28 schizophrenic patients who had a minimum of four points on the CGI at baseline
What problem does this paper attempt to address?